2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
74
Lymphoma, Large B-Cell, Diffuse
55
Lymphoma, Non-Hodgkin
54
Glioblastoma
41
Lymphoma, Mantle-Cell
40
Lymphoma, Follicular
37
Hodgkin Disease
36
Central Nervous System Neoplasms
32
Gliosarcoma
29
Brain Neoplasms
28
Astrocytoma
28
Lymphoma, Large-Cell, Immunoblastic
26
Burkitt Lymphoma
25
Multiple Myeloma
22
Leukemia, Lymphocytic, Chronic, B-Cell
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Glioma
20
Oligodendroglioma
16
Lymphoma, B-Cell, Marginal Zone
15
Neoplasms, Plasma Cell
14
Leukemia
13
Recurrence
10
Lymphoma, B-Cell
9
Lymphoma, T-Cell
8
Waldenstrom Macroglobulinemia
6
Lymphoma, T-Cell, Cutaneous
6
Leukemia, Myeloid, Acute
6
Ependymoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, Large-Cell, Anaplastic
5
Interventions
Rituximab
12
Cyclophosphamide
12
fludarabine
8
dacetuzumab
7
blinatumomab
6
Tacrolimus
6
Busulfan
6
Vincristine
5
Prednisone
5
Etoposide
5
Doxorubicin
5
Bortezomib
5
fludarabine phosphate
4
Valganciclovir
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Methotrexate
3
Melphalan
3
Lenalidomide
3
Ganciclovir
3
Everolimus
3
Dexamethasone
3
Darbepoetin alfa
3
Alemtuzumab
3
tetulomab tetraxetan lu-177
2
ponatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
Carmustine
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts